CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Moderate Buy” by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $71.75.

CRSP has been the topic of several recent research reports. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Morgan Stanley lifted their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. The Goldman Sachs Group lowered their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. Citigroup lowered their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a report on Tuesday, February 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, May 20th.

Insider Activity at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. This trade represents a 12.66% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,021 shares of company stock worth $594,771. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in CRISPR Therapeutics by 182.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company’s stock valued at $66,452,000 after purchasing an additional 1,262,560 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. Capital International Investors increased its position in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after buying an additional 816,789 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of CRISPR Therapeutics by 6,769.1% in the first quarter. Millennium Management LLC now owns 583,733 shares of the company’s stock worth $19,864,000 after acquiring an additional 575,235 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $36.86 on Tuesday. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -8.43 and a beta of 1.88. The stock’s fifty day moving average is $36.95 and its 200-day moving average is $41.77. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The firm’s revenue for the quarter was up 71.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.43) EPS. Analysts forecast that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.